Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma

Background The use of adjuvant chemotherapy (ACT) for stage IB lung adenocarcinoma remains controversial. We examined the benefits of ACT in stage IB patients with tumors composed of solid material. Methods The records of 309 patients with stage IB lung adenocarcinoma who had undergone complete rese...

Full description

Bibliographic Details
Main Authors: Shuhui Cao, Jiajun Teng, Jianlin Xu, Baohui Han, Hua Zhong
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:Thoracic Cancer
Subjects:
Online Access:https://doi.org/10.1111/1759-7714.12942
id doaj-5fd97db4bcfb425c98853b425570c545
record_format Article
spelling doaj-5fd97db4bcfb425c98853b425570c5452020-11-25T00:51:33ZengWileyThoracic Cancer1759-77061759-77142019-02-0110224925510.1111/1759-7714.12942Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinomaShuhui Cao0Jiajun Teng1Jianlin Xu2Baohui Han3Hua Zhong4Department of Pulmonary, Shanghai Chest Hospital Shanghai Jiaotong University Shanghai ChinaDepartment of Pulmonary, Shanghai Chest Hospital Shanghai Jiaotong University Shanghai ChinaDepartment of Pulmonary, Shanghai Chest Hospital Shanghai Jiaotong University Shanghai ChinaDepartment of Pulmonary, Shanghai Chest Hospital Shanghai Jiaotong University Shanghai ChinaDepartment of Pulmonary, Shanghai Chest Hospital Shanghai Jiaotong University Shanghai ChinaBackground The use of adjuvant chemotherapy (ACT) for stage IB lung adenocarcinoma remains controversial. We examined the benefits of ACT in stage IB patients with tumors composed of solid material. Methods The records of 309 patients with stage IB lung adenocarcinoma who had undergone complete resection between 2006 and 2015 were reviewed. All pathological slides were evaluated for the composition of solid material. Results Our data showed that although disease‐free survival (DFS) and overall survival (OS) were not significantly different (P = 0.306 and P = 0.061, respectively) between patients displaying a solid pattern of tumor growth and treated with or without ACT, patients with a solid predominant pattern of tumor growth treated with ACT had longer DFS (hazard ratio 0.359; P = 0.033) and OS (hazard ratio 0.205; P = 0.003). In patients with solid non‐predominant patterns, treatment with ACT had no effect on DFS (P = 0.326) or OS (P = 0.508). Conclusions Postoperative patients with the solid predominant pattern of stage IB lung adenocarcinoma may benefit from ACT, while those with the solid non‐predominant pattern will not.https://doi.org/10.1111/1759-7714.12942Adjuvant chemotherapyearly stagelung adenocarcinomasolid non‐predominantsolid predominant
collection DOAJ
language English
format Article
sources DOAJ
author Shuhui Cao
Jiajun Teng
Jianlin Xu
Baohui Han
Hua Zhong
spellingShingle Shuhui Cao
Jiajun Teng
Jianlin Xu
Baohui Han
Hua Zhong
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
Thoracic Cancer
Adjuvant chemotherapy
early stage
lung adenocarcinoma
solid non‐predominant
solid predominant
author_facet Shuhui Cao
Jiajun Teng
Jianlin Xu
Baohui Han
Hua Zhong
author_sort Shuhui Cao
title Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
title_short Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
title_full Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
title_fullStr Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
title_full_unstemmed Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
title_sort value of adjuvant chemotherapy in patients with resected stage ib solid predominant and solid non‐predominant lung adenocarcinoma
publisher Wiley
series Thoracic Cancer
issn 1759-7706
1759-7714
publishDate 2019-02-01
description Background The use of adjuvant chemotherapy (ACT) for stage IB lung adenocarcinoma remains controversial. We examined the benefits of ACT in stage IB patients with tumors composed of solid material. Methods The records of 309 patients with stage IB lung adenocarcinoma who had undergone complete resection between 2006 and 2015 were reviewed. All pathological slides were evaluated for the composition of solid material. Results Our data showed that although disease‐free survival (DFS) and overall survival (OS) were not significantly different (P = 0.306 and P = 0.061, respectively) between patients displaying a solid pattern of tumor growth and treated with or without ACT, patients with a solid predominant pattern of tumor growth treated with ACT had longer DFS (hazard ratio 0.359; P = 0.033) and OS (hazard ratio 0.205; P = 0.003). In patients with solid non‐predominant patterns, treatment with ACT had no effect on DFS (P = 0.326) or OS (P = 0.508). Conclusions Postoperative patients with the solid predominant pattern of stage IB lung adenocarcinoma may benefit from ACT, while those with the solid non‐predominant pattern will not.
topic Adjuvant chemotherapy
early stage
lung adenocarcinoma
solid non‐predominant
solid predominant
url https://doi.org/10.1111/1759-7714.12942
work_keys_str_mv AT shuhuicao valueofadjuvantchemotherapyinpatientswithresectedstageibsolidpredominantandsolidnonpredominantlungadenocarcinoma
AT jiajunteng valueofadjuvantchemotherapyinpatientswithresectedstageibsolidpredominantandsolidnonpredominantlungadenocarcinoma
AT jianlinxu valueofadjuvantchemotherapyinpatientswithresectedstageibsolidpredominantandsolidnonpredominantlungadenocarcinoma
AT baohuihan valueofadjuvantchemotherapyinpatientswithresectedstageibsolidpredominantandsolidnonpredominantlungadenocarcinoma
AT huazhong valueofadjuvantchemotherapyinpatientswithresectedstageibsolidpredominantandsolidnonpredominantlungadenocarcinoma
_version_ 1725245156620238848